{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T03:07:10Z","timestamp":1769742430392,"version":"3.49.0"},"reference-count":103,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,4,6]],"date-time":"2016-04-06T00:00:00Z","timestamp":1459900800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003381","name":"Minist\u00e9rio da Educa\u00e7\u00e3o e Ci\u00eancia","doi-asserted-by":"publisher","award":["PT2020 UID\/MULTI\/04378\/2013"],"award-info":[{"award-number":["PT2020 UID\/MULTI\/04378\/2013"]}],"id":[{"id":"10.13039\/501100003381","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["POCI\/01\/0145\/FEDER\/007728"],"award-info":[{"award-number":["POCI\/01\/0145\/FEDER\/007728"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Oncology"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1016\/j.tranon.2016.05.004","type":"journal-article","created":{"date-parts":[[2016,8,24]],"date-time":"2016-08-24T12:15:34Z","timestamp":1472040934000},"page":"357-370","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":120,"title":["Biomarker Discovery in Human Prostate Cancer: an Update in Metabolomics Studies"],"prefix":"10.1016","volume":"9","author":[{"given":"Ana Rita","family":"Lima","sequence":"first","affiliation":[]},{"given":"Maria de Lourdes","family":"Bastos","sequence":"additional","affiliation":[]},{"given":"M\u00e1rcia","family":"Carvalho","sequence":"additional","affiliation":[]},{"given":"Paula","family":"Guedes de Pinho","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1016\/j.tranon.2016.05.004_bb0005","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.urolonc.2011.08.002","article-title":"Application of metabolomics to prostate cancer","volume":"29","author":"Trock","year":"2011","journal-title":"Urol Oncol"},{"key":"10.1016\/j.tranon.2016.05.004_bb0010","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.abb.2014.09.002","article-title":"Metabolomics in cell culture\u2014a strategy to study crucial metabolic pathways in cancer development and the response to treatment","volume":"564","author":"Halama","year":"2014","journal-title":"Arch Biochem Biophys"},{"key":"10.1016\/j.tranon.2016.05.004_bb0015","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/ki.2011.314","article-title":"Systems biology of kidney diseases","volume":"81","author":"He","year":"2012","journal-title":"Kidney Int"},{"key":"10.1016\/j.tranon.2016.05.004_bb0020","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.cbpa.2013.06.015","article-title":"Human metabolomics: strategies to understand biology","volume":"17","author":"Ramautar","year":"2013","journal-title":"Curr Opin Chem Biol"},{"key":"10.1016\/j.tranon.2016.05.004_bb0025","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1007\/s11306-014-0659-5","article-title":"Biomarkers in renal cell carcinoma: a metabolomics approach","volume":"10","author":"Monteiro","year":"2014","journal-title":"Metabolomics"},{"key":"10.1016\/j.tranon.2016.05.004_bb0030","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1373\/clinchem.2012.184598","article-title":"New opportunities from the cancer metabolome","volume":"59","author":"Aboud","year":"2013","journal-title":"Clin Chem"},{"key":"10.1016\/j.tranon.2016.05.004_bb0035","doi-asserted-by":"crossref","first-page":"257","DOI":"10.2174\/092986713804806621","article-title":"Metabolomics analysis for biomarker discovery: advances and challenges","volume":"20","author":"Monteiro","year":"2013","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.tranon.2016.05.004_bb0040","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/nrneph.2011.152","article-title":"Metabolomics in the study of kidney diseases","volume":"8","author":"Weiss","year":"2012","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.tranon.2016.05.004_bb0045","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1016\/j.ejca.2014.04.011","article-title":"Analysis of volatile human urinary metabolome by solid-phase microextraction in combination with gas chromatography\u2013mass spectrometry for biomarker discovery: application in a pilot study to discriminate patients with renal cell carcinoma","volume":"50","author":"Monteiro","year":"2014","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.tranon.2016.05.004_bb0050","series-title":"Identification and data processing methods in metabolomics: Future Science Ltd","first-page":"166","article-title":"Potentiality of volatile organic compounds to discriminate patients with cancer by using chemometric tools","author":"Monteiro","year":"2015"},{"key":"10.1016\/j.tranon.2016.05.004_bb0055","doi-asserted-by":"crossref","first-page":"E359","DOI":"10.1002\/ijc.29210","article-title":"Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012","volume":"136","author":"Ferlay","year":"2015","journal-title":"Int J Cancer"},{"key":"10.1016\/j.tranon.2016.05.004_bb0060","doi-asserted-by":"crossref","first-page":"12620","DOI":"10.3390\/ijms140612620","article-title":"The present and future of prostate cancer urine biomarkers","volume":"14","author":"Rigau","year":"2013","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.tranon.2016.05.004_bb0065","first-page":"501213","article-title":"A Comprehensive Review of Contemporary Role of Local Treatment of the Primary Tumor and\/or the Metastases in Metastatic Prostate Cancer","volume":"2014","author":"Aoun","year":"2014","journal-title":"BioMed Research International, vol. 2014, Article ID 501213, 12 pages, 2014"},{"key":"10.1016\/j.tranon.2016.05.004_bb0070","first-page":"890697","article-title":"Novel Tools for Prostate Cancer Prognosis, Diagnosis, and Follow-Up","volume":"2014","author":"Dimakakos","year":"2014","journal-title":"BioMed Research International, vol. 2014, Article ID 890697, 9 pages, 2014"},{"key":"10.1016\/j.tranon.2016.05.004_bb0075","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1002\/pros.22704","article-title":"Metabolomic signatures of aggressive prostate cancer","volume":"73","author":"McDunn","year":"2013","journal-title":"Prostate"},{"key":"10.1016\/j.tranon.2016.05.004_bb0080","doi-asserted-by":"crossref","first-page":"79","DOI":"10.4111\/kju.2011.52.2.79","article-title":"Metabolomics: a novel approach to early and noninvasive prostate cancer detection","volume":"52","author":"Roberts","year":"2011","journal-title":"Korean J Urol"},{"key":"10.1016\/j.tranon.2016.05.004_bb0085","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1056\/NEJMe0901166","article-title":"Screening for prostate cancer\u2014the controversy that refuses to die","volume":"360","author":"Barry","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tranon.2016.05.004_bb0090","doi-asserted-by":"crossref","first-page":"436","DOI":"10.4111\/kju.2014.55.7.436","article-title":"Clinical use of [\u22122]proPSA (p2PSA) and its derivatives (%p2PSA and Prostate Health Index) for the detection of prostate cancer: a review of the literature","volume":"55","author":"Abrate","year":"2014","journal-title":"Korean J Urol"},{"key":"10.1016\/j.tranon.2016.05.004_bb0095","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1097\/01.ju.0000127736.86597.e7","article-title":"Variation in prostate specific antigen results from 2 different assay platforms: clinical impact on 2304 patients undergoing prostate cancer screening","volume":"171","author":"Link","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.tranon.2016.05.004_bb0100","doi-asserted-by":"crossref","first-page":"16ra18","DOI":"10.1126\/scitranslmed.3000513","article-title":"Metabolomic imaging for human prostate cancer detection","volume":"2","author":"Wu","year":"2010","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.tranon.2016.05.004_bb0105","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1093\/jnci\/djr500","article-title":"Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up","volume":"104","author":"Andriole","year":"2012","journal-title":"J Natl Cancer Inst"},{"issue":"Suppl. 1","key":"10.1016\/j.tranon.2016.05.004_bb0110","doi-asserted-by":"crossref","first-page":"S60","DOI":"10.1007\/s00259-013-2379-x","article-title":"Metabolomic imaging of prostate cancer with magnetic resonance spectroscopy and mass spectrometry","volume":"40","author":"Spur","year":"2013","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.tranon.2016.05.004_bb0115","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.eururo.2012.09.033","article-title":"Contemporary role of systematic prostate biopsies: indications, techniques, and implications for patient care","volume":"63","author":"Ukimura","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.tranon.2016.05.004_bb0120","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1126\/science.123.3191.309","article-title":"On the origin of cancer cells","volume":"123","author":"Warburg","year":"1956","journal-title":"Science"},{"key":"10.1016\/j.tranon.2016.05.004_bb0125","first-page":"319","article-title":"\u00dcber den Stoffwechsel der Carcinom-Zelle","volume":"152","author":"Warburg","year":"1924","journal-title":"Biochem Z"},{"key":"10.1016\/j.tranon.2016.05.004_bb0130","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/cas.12085","article-title":"Cancer metabolism: key players in metabolic reprogramming","volume":"104","author":"Soga","year":"2013","journal-title":"Cancer Sci"},{"key":"10.1016\/j.tranon.2016.05.004_bb0135","doi-asserted-by":"crossref","first-page":"18333","DOI":"10.3390\/ijms151018333","article-title":"Lactate transporters in the context of prostate cancer metabolism: what do we know?","volume":"15","author":"Pertega-Gomes","year":"2014","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.tranon.2016.05.004_bb0140","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/pros.2990180104","article-title":"Concepts of citrate production and secretion by prostate. 1. Metabolic relationships","volume":"18","author":"Costello","year":"1991","journal-title":"Prostate"},{"key":"10.1016\/j.tranon.2016.05.004_bb0145","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/pcan.2008.19","article-title":"Prostatic fluid electrolyte composition for the screening of prostate cancer: a potential solution to a major problem","volume":"12","author":"Costello","year":"2009","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.tranon.2016.05.004_bb0150","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1136\/jcp.2005.027664","article-title":"Altered metabolism and mitochondrial genome in prostate cancer","volume":"59","author":"Dakubo","year":"2006","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.tranon.2016.05.004_bb0155","doi-asserted-by":"crossref","first-page":"28875","DOI":"10.1074\/jbc.272.46.28875","article-title":"Zinc inhibition of mitochondrial aconitase and its importance in citrate metabolism of prostate epithelial cells","volume":"272","author":"Costello","year":"1997","journal-title":"J Biol Chem"},{"key":"10.1016\/j.tranon.2016.05.004_bb0160","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1159\/000012183","article-title":"The intermediary metabolism of the prostate: a key to understanding the pathogenesis and progression of prostate malignancy","volume":"59","author":"Costello","year":"2000","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.tranon.2016.05.004_bb0165","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1002\/pros.20177","article-title":"Peroxisomal branched chain fatty acid beta-oxidation pathway is upregulated in prostate cancer","volume":"63","author":"Zha","year":"2005","journal-title":"Prostate"},{"key":"10.1016\/j.tranon.2016.05.004_bb0170","first-page":"369","article-title":"Dominant uptake of fatty acid over glucose by prostate cells: a potential new diagnostic and therapeutic approach","volume":"30","author":"Liu","year":"2010","journal-title":"Anticancer Res"},{"key":"10.1016\/j.tranon.2016.05.004_bb0175","doi-asserted-by":"crossref","first-page":"e103","DOI":"10.1038\/oncsis.2014.18","article-title":"Regulation of the pentose phosphate pathway by an androgen receptor-mTOR\u2013mediated mechanism and its role in prostate cancer cell growth","volume":"3","author":"Tsouko","year":"2014","journal-title":"Oncogenesis"},{"key":"10.1016\/j.tranon.2016.05.004_bb0180","doi-asserted-by":"crossref","first-page":"7947","DOI":"10.1074\/jbc.M109.092759","article-title":"Androgen receptor survival signaling is blocked by anti-beta2-microglobulin monoclonal antibody via a MAPK\/lipogenic pathway in human prostate cancer cells","volume":"285","author":"Huang","year":"2010","journal-title":"J Biol Chem"},{"key":"10.1016\/j.tranon.2016.05.004_bb0185","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1158\/1541-7786.MCR-11-0206","article-title":"Activation of androgen receptor, lipogenesis, and oxidative stress converged by SREBP-1 is responsible for regulating growth and progression of prostate cancer cells","volume":"10","author":"Huang","year":"2012","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.tranon.2016.05.004_bb0190","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1586\/14737159.2015.1069711","article-title":"Metabolomic profiling for the identification of novel diagnostic markers in prostate cancer","volume":"15","author":"Lucarelli","year":"2015","journal-title":"Expert Rev Mol Diagn"},{"key":"10.1016\/j.tranon.2016.05.004_bb0195","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1002\/path.4518","article-title":"Targeting ASCT2-mediated glutamine uptake blocks prostate cancer growth and tumour development","volume":"236","author":"Wang","year":"2015","journal-title":"J Pathol"},{"key":"10.1016\/j.tranon.2016.05.004_bb0200","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.bbrc.2014.11.105","article-title":"Elevated expression of glutaminase confers glucose utilization via glutaminolysis in prostate cancer","volume":"456","author":"Pan","year":"2015","journal-title":"Biochem Biophys Res Commun"},{"issue":"2","key":"10.1016\/j.tranon.2016.05.004_bb0205","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s00018-015-2070-4","article-title":"Reprogramming of glucose, fatty acid and amino acid metabolism for cancer progression","volume":"73","author":"Li","year":"2015","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.tranon.2016.05.004_bb0210","doi-asserted-by":"crossref","first-page":"3984","DOI":"10.4161\/cc.8.23.10238","article-title":"The reverse Warburg effect: aerobic glycolysis in cancer associated fibroblasts and the tumor stroma","volume":"8","author":"Pavlides","year":"2009","journal-title":"Cell Cycle"},{"key":"10.1016\/j.tranon.2016.05.004_bb0215","doi-asserted-by":"crossref","first-page":"5130","DOI":"10.1158\/0008-5472.CAN-12-1949","article-title":"Reciprocal metabolic reprogramming through lactate shuttle coordinately influences tumor-stroma interplay","volume":"72","author":"Fiaschi","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.tranon.2016.05.004_bb0220","doi-asserted-by":"crossref","first-page":"9","DOI":"10.5173\/ceju.2011.01.art2","article-title":"Urine markers and prostate cancer","volume":"64","author":"Wilkosz","year":"2011","journal-title":"Cent Eur J Urol"},{"key":"10.1016\/j.tranon.2016.05.004_bb0225","doi-asserted-by":"crossref","first-page":"e65880","DOI":"10.1371\/journal.pone.0065880","article-title":"Application of holistic liquid chromatography\u2013high resolution mass spectrometry based urinary metabolomics for prostate cancer detection and biomarker discovery","volume":"8","author":"Zhang","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.tranon.2016.05.004_bb0230","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1097\/01.ju.0000148949.72314.d7","article-title":"A decrease in 1H nuclear magnetic resonance spectroscopically determined citrate in human seminal fluid accompanies the development of prostate adenocarcinoma","volume":"173","author":"Averna","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.tranon.2016.05.004_bb0235","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/nbm.2979","article-title":"High-resolution NMR spectroscopy of human body fluids and tissues in relation to prostate cancer","volume":"27","author":"Kumar","year":"2014","journal-title":"NMR Biomed"},{"key":"10.1016\/j.tranon.2016.05.004_bb0240","doi-asserted-by":"crossref","first-page":"77","DOI":"10.2217\/bmm.14.110","article-title":"Seminal fluid: a useful source of prostate cancer biomarkers?","volume":"9","author":"Roberts","year":"2015","journal-title":"Biomark Med"},{"key":"10.1016\/j.tranon.2016.05.004_bb0245","doi-asserted-by":"crossref","first-page":"2914","DOI":"10.1002\/ijc.28303","article-title":"Tissue metabolite profiling identifies differentiating and prognostic biomarkers for prostate carcinoma","volume":"133","author":"Jung","year":"2013","journal-title":"Int J Cancer"},{"key":"10.1016\/j.tranon.2016.05.004_bb0250","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1089\/omi.2012.0090","article-title":"Cell metabolomics","volume":"17","author":"Zhang","year":"2013","journal-title":"OMICS"},{"key":"10.1016\/j.tranon.2016.05.004_bb0255","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.drudis.2010.06.012","article-title":"Cell culture metabolomics: applications and future directions","volume":"15","author":"Cuperlovic-Culf","year":"2010","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.tranon.2016.05.004_bb0260","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1002\/pros.22665","article-title":"Metabolic reprogramming and validation of hyperpolarized 13C lactate as a prostate cancer biomarker using a human prostate tissue slice culture bioreactor","volume":"73","author":"Keshari","year":"2013","journal-title":"Prostate"},{"key":"10.1016\/j.tranon.2016.05.004_bb0265","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1038\/nature07762","article-title":"Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression","volume":"457","author":"Sreekumar","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.tranon.2016.05.004_bb0270","doi-asserted-by":"crossref","first-page":"13893","DOI":"10.3390\/ijms140713893","article-title":"Sarcosine as a potential prostate cancer biomarker\u2014a review","volume":"14","author":"Cernei","year":"2013","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.tranon.2016.05.004_bb0275","doi-asserted-by":"crossref","first-page":"9022","DOI":"10.1021\/ac1019914","article-title":"Quantitative determination of sarcosine and related compounds in urinary samples by liquid chromatography with tandem mass spectrometry","volume":"82","author":"Jiang","year":"2010","journal-title":"Anal Chem"},{"key":"10.1016\/j.tranon.2016.05.004_bb0280","doi-asserted-by":"crossref","first-page":"e22486","DOI":"10.1371\/journal.pone.0022486","article-title":"Serum methionine metabolites are risk factors for metastatic prostate cancer progression","volume":"6","author":"Stabler","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.tranon.2016.05.004_bb0285","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.aca.2011.09.015","article-title":"Fully automated solid-phase microextraction-fast gas chromatography\u2013mass spectrometry method using a new ionic liquid column for high-throughput analysis of sarcosine and N-ethylglycine in human urine and urinary sediments","volume":"707","author":"Bianchi","year":"2011","journal-title":"Anal Chim Acta"},{"key":"10.1016\/j.tranon.2016.05.004_bb0290","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1002\/pros.21286","article-title":"A multiplex model of combining gene-based, protein-based, and metabolite-based with positive and negative markers in urine for the early diagnosis of prostate cancer","volume":"71","author":"Cao","year":"2011","journal-title":"Prostate"},{"key":"10.1016\/j.tranon.2016.05.004_bb0295","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1593\/neo.13314","article-title":"The role of sarcosine metabolism in prostate cancer progression","volume":"15","author":"Khan","year":"2013","journal-title":"Neoplasia"},{"key":"10.1016\/j.tranon.2016.05.004_bb0300","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s00216-011-5098-9","article-title":"GC\/MS-based metabolomic approach to validate the role of urinary sarcosine and target biomarkers for human prostate cancer by microwave-assisted derivatization","volume":"401","author":"Wu","year":"2011","journal-title":"Anal Bioanal Chem"},{"key":"10.1016\/j.tranon.2016.05.004_bb0305","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.eururo.2010.01.035","article-title":"Sarcosine in urine after digital rectal examination fails as a marker in prostate cancer detection and identification of aggressive tumours","volume":"58","author":"Jentzmik","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.tranon.2016.05.004_bb0310","doi-asserted-by":"crossref","first-page":"3619","DOI":"10.1002\/jssc.201100572","article-title":"Is sarcosine a biomarker for prostate cancer?","volume":"34","author":"Issaq","year":"2011","journal-title":"J Sep Sci"},{"key":"10.1016\/j.tranon.2016.05.004_bb0315","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.jpba.2014.12.026","article-title":"Urine metabolic fingerprinting using LC-MS and GC-MS reveals metabolite changes in prostate cancer: A pilot study","volume":"111","author":"Struck-Lewicka","year":"2015","journal-title":"J Pharm Biomed Anal"},{"key":"10.1016\/j.tranon.2016.05.004_bb0320","doi-asserted-by":"crossref","first-page":"e0143283","DOI":"10.1371\/journal.pone.0143283","article-title":"Urinary volatile organic compounds for the detection of prostate cancer","volume":"10","author":"Khalid","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.tranon.2016.05.004_bb0325","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1109\/JSEN.2009.2035771","article-title":"Application of similarity coefficients to predict disease using volatile organic compounds","volume":"10","author":"Steve Smith","year":"2010","journal-title":"IEEE Sens J"},{"key":"10.1016\/j.tranon.2016.05.004_bb0330","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1002\/pros.22514","article-title":"Serum sarcosine increases the accuracy of prostate cancer detection in patients with total serum PSA less than 4.0 ng\/ml","volume":"72","author":"Lucarelli","year":"2012","journal-title":"Prostate"},{"key":"10.1016\/j.tranon.2016.05.004_bb0335","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1093\/carcin\/bgt176","article-title":"Prospective evaluation of serum sarcosine and risk of prostate cancer in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial","volume":"34","author":"Koutros","year":"2013","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.tranon.2016.05.004_bb0340","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1021\/pr5011108","article-title":"Metabolomics-derived prostate cancer biomarkers: fact or fiction?","volume":"14","author":"Kumar","year":"2015","journal-title":"J Proteome Res"},{"key":"10.1016\/j.tranon.2016.05.004_bb0345","doi-asserted-by":"crossref","first-page":"3444","DOI":"10.1021\/pr500409q","article-title":"Feasibility of detecting prostate cancer by ultraperformance liquid chromatography\u2013mass spectrometry serum metabolomics","volume":"13","author":"Zang","year":"2014","journal-title":"J Proteome Res"},{"key":"10.1016\/j.tranon.2016.05.004_bb0350","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.3945\/ajcn.2008.26369","article-title":"Fatty acid composition of plasma phospholipids and risk of prostate cancer in a case\u2013control analysis nested within the European Prospective Investigation into Cancer and Nutrition","volume":"88","author":"Crowe","year":"2008","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.tranon.2016.05.004_bb0355","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1158\/1055-9965.EPI-08-1193","article-title":"One-carbon metabolism and prostate cancer risk: prospective investigation of seven circulating B vitamins and metabolites","volume":"18","author":"Johansson","year":"2009","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.tranon.2016.05.004_bb0360","doi-asserted-by":"crossref","first-page":"e48889","DOI":"10.1371\/journal.pone.0048889","article-title":"Identification of plasma lipid biomarkers for prostate cancer by lipidomics and bioinformatics","volume":"7","author":"Zhou","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.tranon.2016.05.004_bb0365","doi-asserted-by":"crossref","first-page":"e24143","DOI":"10.1371\/journal.pone.0024143","article-title":"Plasma free amino acid profiling of five types of cancer patients and its application for early detection","volume":"6","author":"Miyagi","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.tranon.2016.05.004_bb0370","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1038\/bjc.2015.411","article-title":"Metabolic markers in blood can separate prostate cancer from benign prostatic hyperplasia","volume":"113","author":"Giskeodegard","year":"2015","journal-title":"Br J Cancer"},{"key":"10.1016\/j.tranon.2016.05.004_bb0375","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1093\/bioinformatics\/btn506","article-title":"A new rule-based algorithm for identifying metabolic markers in prostate cancer using tandem mass spectrometry","volume":"24","author":"Osl","year":"2008","journal-title":"Bioinformatics"},{"key":"10.1016\/j.tranon.2016.05.004_bb0380","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.7314\/APJCP.2014.15.2.1031","article-title":"Role of hyperinsulinemia in increased risk of prostate cancer: a case control study from Kathmandu Valley","volume":"15","author":"Pandeya","year":"2014","journal-title":"Asian Pac J Cancer Prev"},{"key":"10.1016\/j.tranon.2016.05.004_bb0385","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/pcan.2013.5","article-title":"Hyperglycemia and prostate cancer recurrence in men treated for localized prostate cancer","volume":"16","author":"Wright","year":"2013","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.tranon.2016.05.004_bb0390","doi-asserted-by":"crossref","first-page":"3677","DOI":"10.1158\/1078-0432.CCR-11-3209","article-title":"Prospective study of changes in the metabolomic profiles of men during their first three months of androgen deprivation therapy for prostate cancer","volume":"18","author":"Saylor","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.tranon.2016.05.004_bb0395","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/BF02552165","article-title":"Zinc concentration in human prostatic fluid: normal, chronic prostatitis, adenoma and cancer","volume":"28","author":"Zaichick","year":"1996","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.tranon.2016.05.004_bb0400","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1002\/(SICI)1097-0045(19970301)30:4<248::AID-PROS4>3.0.CO;2-H","article-title":"Proton MRS of human prostatic fluid: correlations between citrate, spermine, and myo-inositol levels and changes with disease","volume":"30","author":"Lynch","year":"1997","journal-title":"Prostate"},{"key":"10.1016\/j.tranon.2016.05.004_bb0405","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1016\/j.juro.2006.07.054","article-title":"Citrate concentrations in human seminal fluid and expressed prostatic fluid determined via 1H nuclear magnetic resonance spectroscopy outperform prostate specific antigen in prostate cancer detection","volume":"176","author":"Kline","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.tranon.2016.05.004_bb0410","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1002\/pros.20727","article-title":"The metabolites citrate, myo-inositol, and spermine are potential age-independent markers of prostate cancer in human expressed prostatic secretions","volume":"68","author":"Serkova","year":"2008","journal-title":"Prostate"},{"key":"10.1016\/j.tranon.2016.05.004_bb0415","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.juro.2010.09.077","article-title":"Sarcosine in prostate cancer tissue is not a differential metabolite for prostate cancer aggressiveness and biochemical progression","volume":"185","author":"Jentzmik","year":"2011","journal-title":"J Urol"},{"key":"10.1016\/j.tranon.2016.05.004_bb0420","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s10334-008-0156-9","article-title":"High resolution magic angle spinning NMR spectroscopy for metabolic assessment of cancer presence and Gleason score in human prostate needle biopsies","volume":"21","author":"van Asten","year":"2008","journal-title":"MAGMA"},{"key":"10.1016\/j.tranon.2016.05.004_bb0425","first-page":"3398","article-title":"The classification of benign and malignant human prostate tissue by multivariate analysis of 1H magnetic resonance spectra","volume":"57","author":"Hahn","year":"1997","journal-title":"Cancer Res"},{"key":"10.1016\/j.tranon.2016.05.004_bb0430","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/S0730-725X(99)00006-5","article-title":"In vivo proton magnetic resonance spectroscopy of diseased prostate: spectroscopic features of malignant versus benign pathology","volume":"17","author":"Garcia-Segura","year":"1999","journal-title":"Magn Reson Imaging"},{"key":"10.1016\/j.tranon.2016.05.004_bb0435","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S0014-5793(01)02329-8","article-title":"Non-destructive quantitation of spermine in human prostate tissue samples using HRMAS 1H NMR spectroscopy at 9.4 T","volume":"494","author":"Cheng","year":"2001","journal-title":"FEBS Lett"},{"key":"10.1016\/j.tranon.2016.05.004_bb0440","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1148\/radiol.2281011808","article-title":"Pathologic characterization of human prostate tissue with proton MR spectroscopy","volume":"228","author":"Swindle","year":"2003","journal-title":"Radiology"},{"key":"10.1016\/j.tranon.2016.05.004_bb0445","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1002\/mrm.10614","article-title":"Proton HR-MAS spectroscopy and quantitative pathologic analysis of MRI\/3D-MRSI-targeted postsurgical prostate tissues","volume":"50","author":"Swanson","year":"2003","journal-title":"Magn Reson Med"},{"key":"10.1016\/j.tranon.2016.05.004_bb0450","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1002\/mrm.21694","article-title":"Evaluation of lactate and alanine as metabolic biomarkers of prostate cancer using 1H HR-MAS spectroscopy of biopsy tissues","volume":"60","author":"Tessem","year":"2008","journal-title":"Magn Reson Med"},{"key":"10.1016\/j.tranon.2016.05.004_bb0455","doi-asserted-by":"crossref","first-page":"e62375","DOI":"10.1371\/journal.pone.0062375","article-title":"Spermine and citrate as metabolic biomarkers for assessing prostate cancer aggressiveness","volume":"8","author":"Giskeodegard","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.tranon.2016.05.004_bb0460","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/mrm.21647","article-title":"Quantification of choline- and ethanolamine-containing metabolites in human prostate tissues using 1H HR-MAS total correlation spectroscopy","volume":"60","author":"Swanson","year":"2008","journal-title":"Magn Reson Med"},{"key":"10.1016\/j.tranon.2016.05.004_bb0465","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1002\/pros.21103","article-title":"Retrospective analysis of prostate cancer recurrence potential with tissue metabolomic profiles","volume":"70","author":"Maxeiner","year":"2010","journal-title":"Prostate"},{"key":"10.1016\/j.tranon.2016.05.004_bb0470","doi-asserted-by":"crossref","first-page":"39","DOI":"10.4137\/BMI.S6794","article-title":"H HRMAS NMR derived bio-markers related to tumor grade, tumor cell fraction, and cell proliferation in prostate tissue samples","volume":"6","author":"Stenman","year":"2011","journal-title":"Biomark Insights"},{"key":"10.1016\/j.tranon.2016.05.004_bb0475","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s10334-009-0187-x","article-title":"Detection of polyunsaturated omega-6 fatty acid in human malignant prostate tissue by 1D and 2D high-resolution magic angle spinning NMR spectroscopy","volume":"22","author":"Stenman","year":"2009","journal-title":"MAGMA"},{"key":"10.1016\/j.tranon.2016.05.004_bb0480","doi-asserted-by":"crossref","first-page":"e14175","DOI":"10.1371\/journal.pone.0014175","article-title":"Metabolomic characterization of human prostate cancer bone metastases reveals increased levels of cholesterol","volume":"5","author":"Thysell","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.tranon.2016.05.004_bb0485","doi-asserted-by":"crossref","first-page":"e21417","DOI":"10.1371\/journal.pone.0021417","article-title":"Metabolomic profiling reveals a role for androgen in activating amino acid metabolism and methylation in prostate cancer cells","volume":"6","author":"Putluri","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.tranon.2016.05.004_bb0490","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/j.biocel.2010.07.003","article-title":"Metabolic signatures of malignant progression in prostate epithelial cells","volume":"43","author":"Teahan","year":"2011","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1016\/j.tranon.2016.05.004_bb0495","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1021\/pr401106h","article-title":"Metabolomic profiling identifies biochemical pathways associated with castration-resistant prostate cancer","volume":"13","author":"Kaushik","year":"2014","journal-title":"J Proteome Res"},{"key":"10.1016\/j.tranon.2016.05.004_bb0500","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1016\/j.biocel.2012.08.013","article-title":"Androgen-responsive and nonresponsive prostate cancer cells present a distinct glycolytic metabolism profile","volume":"44","author":"Vaz","year":"2012","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1016\/j.tranon.2016.05.004_bb0505","doi-asserted-by":"crossref","first-page":"742","DOI":"10.4161\/cbt.7.5.5746","article-title":"Comparison of radiolabeled choline and ethanolamine as probe for cancer detection","volume":"7","author":"Mintz","year":"2008","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.tranon.2016.05.004_bb0510","doi-asserted-by":"crossref","first-page":"e26155","DOI":"10.1371\/journal.pone.0026155","article-title":"Magnetic resonance spectroscopy detectable metabolomic fingerprint of response to antineoplastic treatment","volume":"6","author":"Lodi","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.tranon.2016.05.004_bb0515","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1002\/nbm.3101","article-title":"NMR-based evaluation of the metabolic profile and response to dichloroacetate of human prostate cancer cells","volume":"27","author":"Kailavasan","year":"2014","journal-title":"NMR Biomed"}],"container-title":["Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523316300511?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523316300511?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T14:31:24Z","timestamp":1761834684000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1936523316300511"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":103,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["S1936523316300511"],"URL":"https:\/\/doi.org\/10.1016\/j.tranon.2016.05.004","relation":{},"ISSN":["1936-5233"],"issn-type":[{"value":"1936-5233","type":"print"}],"subject":[],"published":{"date-parts":[[2016,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biomarker Discovery in Human Prostate Cancer: an Update in Metabolomics Studies","name":"articletitle","label":"Article Title"},{"value":"Translational Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tranon.2016.05.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"name":"copyright","label":"Copyright"}]}}